Related references
Note: Only part of the references are listed.Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma
Yang Xu et al.
CLINICAL CANCER RESEARCH (2011)
Smac Modulates Chemosensitivity in Head and Neck Cancer Cells through the Mitochondrial Apoptotic Pathway
Quanhong Sun et al.
CLINICAL CANCER RESEARCH (2011)
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
Elton Rexhepaj et al.
BMC CANCER (2010)
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
Laura G. Estevez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani et al.
BREAST CANCER RESEARCH (2009)
SMAC mimetics sensitize nonsteroidal anti-inflammatory drug-induced apoptosis by promoting caspase-3-mediated cytochrome c release
Alexander Bank et al.
CANCER RESEARCH (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of Smac/DIABLO in cancer progression
Gustavo Martinez-Ruiz et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells
Tamer E. Fandy et al.
MOLECULAR CANCER (2008)
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
Chafika Mazouni et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Novel link between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1
Wei Xie et al.
NUCLEIC ACIDS RESEARCH (2006)
Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo
N Hayashi et al.
PROSTATE (2005)
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma
ET Shinohara et al.
CANCER (2005)
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance
Y Mizutani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment
M Colleoni et al.
CLINICAL CANCER RESEARCH (2004)
Survivin is an independent prognostic marker for risk stratification of breast cancer patients
PN Span et al.
CLINICAL CHEMISTRY (2004)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Survivin gene expression in early-stage non-small cell lung cancer
M Falleni et al.
JOURNAL OF PATHOLOGY (2003)
Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis
ZY Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway
IA McNeish et al.
EXPERIMENTAL CELL RESEARCH (2003)
Prognostic importance of survivin in breast cancer
SM Kennedy et al.
BRITISH JOURNAL OF CANCER (2003)
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
S Fulda et al.
NATURE MEDICINE (2002)
Cell death inhibition: Keeping caspases in check
L Goyal
CELL (2001)
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
CY Du et al.
CELL (2000)
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
AM Verhagen et al.
CELL (2000)
Share Paper
